Nausea and Vomiting Remain a Significant Clinical Problem Joseph A Roscoe, PhD, Gary R Morrow, PhD, MS, Jane T Hickok, MD, MPH, Robert M Stern, PhD Journal of Pain and Symptom Management Volume 20, Issue 2, Pages 113-121 (August 2000) DOI: 10.1016/S0885-3924(00)00159-7
Fig. 1 Proportion of patients receiving 5-HT3 receptor antagonists Journal of Pain and Symptom Management 2000 20, 113-121DOI: (10.1016/S0885-3924(00)00159-7)
Fig. 2 Vomiting measured at four treatment cycles. Symbols represent proportion of patients reporting symptom Journal of Pain and Symptom Management 2000 20, 113-121DOI: (10.1016/S0885-3924(00)00159-7)
Fig. 3 Nausea measured at four treatment cycles. Symbols represent proportion of patients reporting symptom Journal of Pain and Symptom Management 2000 20, 113-121DOI: (10.1016/S0885-3924(00)00159-7)
Fig. 4 Average duration per incident Journal of Pain and Symptom Management 2000 20, 113-121DOI: (10.1016/S0885-3924(00)00159-7)